SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Sanofi-Aventis: Click to view the issuer\'s details

Last update : 29/03/2019  >View issuer details

2019.07.02 | 22:30 | Permanent Information Releases / Notification of availability

English version HTML (w) Mail

puce Sanofi : Availability of the Pre-quarterly Results Communication - HTML (w)

2019.07.02 | 22:30 | Permanent Information Releases / Notification of availability

French version HTML (w) Mail

puce Sanofi : Mise en ligne du document «Pre-quarterly Results Communication » - HTML (w)

2019.07.01 | 16:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union - HTML (w)

2019.06.28 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - HTML (w)

2019.06.27 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate - HTML (w)

2019.06.27 | 07:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi : La FDA va examiner le dossier du candidat-vaccin méningococcique MenQuadfi - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi : La FDA approuve Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne - HTML (w)

2019.06.21 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma - HTML (w)

2019.06.18 | 07:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi et Google vont développer un nouveau laboratoire d’innovation en santé - HTML (w)

2019.06.17 | 18:28 | Share History / Voting Rights and Number of Shares

English version HTML (w) Mail

puce Sanofi: information concerning the total number of voting rights and shares, May 2019 - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2696